Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2019-03-11 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Laurus Labs has received two approvals from the US FDA for pharmaceutical products. It contains no financial data, no detailed report, no meeting materials, no voting results, no management changes, no earnings data, and no regulatory certifications. It is a corporate announcement about product approvals, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being published or attached. The content is a straightforward corporate press release about product approvals, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-03-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is extremely short (277 characters) and contains only a table listing a date, analyst/investor names, type of interaction, and location. There is no financial data, no report content, no regulatory references, or any indication of a formal filing. It appears to be a schedule or record of investor meetings rather than a financial report or announcement. Given the lack of substantive content and the nature of the text, it does not fit into any specific detailed filing category. The best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not neatly fit elsewhere.
2019-02-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Laurus Labs Limited Q3 FY2019 Earnings Conference Call held on February 1, 2019. It includes management's opening remarks, financial highlights, business updates, and a Q&A session with analysts and investors. The content focuses on quarterly financial results, business performance, product approvals, and future outlook. The presence of detailed financial figures, discussion of EBITDA, revenues, margins, and operational updates confirms this is a full earnings call transcript rather than a brief earnings release or presentation. Therefore, the document fits the category of a Call Transcript (CT).
2019-02-08 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Laurus Labs has received tentative approval from the US FDA for a pharmaceutical product and also received an Establishment Inspection Report (EIR) from the US FDA for one of its manufacturing units. The content focuses on regulatory approval and manufacturing updates rather than financial results, management changes, or shareholder information. The document length is 3829 characters, which is relatively short and typical for a press release. There is no indication that this is a full financial report, audit report, or any other detailed filing. It is an announcement of regulatory approval and inspection results, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-02-03 English
Investor Presentation
Regulatory Filings
2019-01-31 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the quarterly and nine-month financial results for Laurus Labs Limited for Q3 FY19. It includes revenue, EBITDA, PAT, EPS, and business highlights, which are typical contents of an earnings release. The document is about 5800 characters long, which is consistent with a detailed earnings release rather than a brief announcement or a full annual report. There is no indication that this is a full annual report (10-K) or an interim report with full financial statements, but rather a summary of quarterly results. The presence of forward-looking statements and management comments further supports classification as an Earnings Release (ER). Q3 2019
2019-01-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.